A hospital in the US is among the first to offer rapid genome sequencing of critically ill newborns to help identify the cause of their illnesses, which could save their lives. This technology could be used on healthy babies too. But some experts raise concerns about sequencing every baby at birth.
Artios Pharma, a U.K. based company in Cambridge, has raised $84 million to take DNA damage response (DDR) programs to the next level of clinical proof of concept.
In a major breakthrough in cancer research, a team of scientists from the University of Toronto, The Institute of Cancer Research, London, The Netherlands Cancer Institute and the University of Bern have discovered how cells repair damaged strands of DNA. They revealed a brand new protein complex in cells that protect broken DNA ends and causes its repair, in their study published in Nature on Wednesday.
Precision medicine is an emerging approach for disease treatment where genes, the environment and lifestyle of each person is taken into account.
Cambridge, Mass.-based Biotech startup Accent Therapeutics announced $40 million A series funding to develop cancer treatment based on epitranscriptomics, an RNA-modifying protein (RMPs) which have been connected to recent cancer studies.
SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for its oral formulation of TPOXX® (tecovirimat).
The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
Boehringer Ingelheim announced the approval of a new indication for afatinib (Gilotrif), as the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (NDA) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Researchers at the University of California, Riverside, have shown that it is possible for transgenic mosquitos to stably express the Cas9 enzyme in their germline. Cas9 addition will allow the utilization of the CRISPR gene editing tool to carry out efficient and highly targeted changes to the DNA of the mosquitoes.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.